Aberdeen Group plc lifted its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.9% during the third quarter, HoldingsChannel.com reports. The firm owned 695,689 shares of the company’s stock after purchasing an additional 12,871 shares during the period. Eli Lilly and Company accounts for about 0.8% of Aberdeen Group plc’s portfolio, making the stock its 17th largest position. Aberdeen Group plc’s holdings in Eli Lilly and Company were worth $804,968,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the stock. Marshall & Sterling Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares in the last quarter. Torren Management LLC raised its position in Eli Lilly and Company by 357.1% during the third quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after acquiring an additional 25 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $42,000. Foresight Capital Management Advisors Inc. acquired a new position in Eli Lilly and Company during the third quarter worth about $49,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $64,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Insider Activity at Eli Lilly and Company
In other news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.
Key Stories Impacting Eli Lilly and Company
- Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
- Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study
- Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations
Analyst Upgrades and Downgrades
Several research firms have issued reports on LLY. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Monday, November 9th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, Leerink Partners lifted their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,416.64.
View Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Trading Up 1.2%
Shares of Eli Lilly and Company stock opened at $1,444.05 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00. The stock has a 50 day moving average price of $1,242.25 and a two-hundred day moving average price of $1,110.30. The stock has a market capitalization of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the firm posted $7.02 EPS. The business’s revenue was up 38.6% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 22.46%.
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
